{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:10:19Z","timestamp":1739319019525,"version":"3.37.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Topics in Companion Animal Medicine"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1053\/j.tcam.2009.02.003","type":"journal-article","created":{"date-parts":[[2009,9,3]],"date-time":"2009-09-03T11:22:56Z","timestamp":1251976976000},"page":"151-156","source":"Crossref","is-referenced-by-count":12,"title":["Intravenous Aminobisphosphonates for Managing Complications of Malignant Osteolysis in Companion Animals"],"prefix":"10.1053","volume":"24","author":[{"given":"Timothy M.","family":"Fan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1053\/j.tcam.2009.02.003_bib1","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1210\/jcem-73-6-1309","article-title":"Parathyroid hormone-related protein: elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer","volume":"73","author":"Grill","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1053\/j.tcam.2009.02.003_bib2","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/0041-008X(72)90007-5","article-title":"Metabolism of disodium ethane-1-hydroxy-1,1-diphosphonate (disodium etidronate) in the rat, rabbit, dog and monkey","volume":"21","author":"Michael","year":"1972","journal-title":"Toxicol Appl Pharmacol"},{"issue":"2","key":"10.1053\/j.tcam.2009.02.003_bib3","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","article-title":"Bisphosphonates: a review of their pharmacokinetic properties","volume":"18","author":"Lin","year":"1996","journal-title":"Bone"},{"issue":"9","key":"10.1053\/j.tcam.2009.02.003_bib4","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/0091270004267594","article-title":"Ibandronate: a clinical pharmacological and pharmacokinetic update","volume":"44","author":"Barrett","year":"2004","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"10.1053\/j.tcam.2009.02.003_bib5","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/jbmr.5650070507","article-title":"Retention of etidronate in human, dog, and rat","volume":"7","author":"Kasting","year":"1992","journal-title":"J Bone Miner Res"},{"issue":"4","key":"10.1053\/j.tcam.2009.02.003_bib6","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0090-9556(25)08706-9","article-title":"Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats","volume":"20","author":"Lin","year":"1992","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1053\/j.tcam.2009.02.003_bib7","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S0090-9556(25)08729-X","article-title":"Renal handling of alendronate in rats","volume":"20","author":"Lin","year":"1992","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1053\/j.tcam.2009.02.003_bib8","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/S0090-9556(25)08972-X","article-title":"Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals","volume":"19","author":"Lin","year":"1991","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1053\/j.tcam.2009.02.003_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/aja.1001610102","article-title":"The hematogenous origin of osteoclasts: experimental evidence from osteopetrotic (microphthalmic) mice treated with spleen cells from beige mouse donors","volume":"161","author":"Marks","year":"1981","journal-title":"Am J Anat"},{"issue":"10","key":"10.1053\/j.tcam.2009.02.003_bib10","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/jbmr.5650101008","article-title":"Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo","volume":"10","author":"Hughes","year":"1995","journal-title":"J Bone Miner Res"},{"issue":"5","key":"10.1053\/j.tcam.2009.02.003_bib11","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0026-895X(25)09541-0","article-title":"Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages","volume":"50","author":"Selander","year":"1996","journal-title":"Mol Pharmacol"},{"issue":"12","key":"10.1053\/j.tcam.2009.02.003_bib12","first-page":"1152","article-title":"Alendronate-associated esophageal injury: pathologic and endoscopic features","volume":"12","author":"Abraham","year":"1999","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1053\/j.tcam.2009.02.003_bib13","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2165\/00002018-199614030-00003","article-title":"Adverse effects of bisphosphonates","volume":"14","author":"Adami","year":"1996","journal-title":"Drug Saf"},{"issue":"4 Suppl 11","key":"10.1053\/j.tcam.2009.02.003_bib14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0093-7754(01)90232-5","article-title":"Dosing regimens and main adverse events of bisphosphonates","volume":"28","author":"Body","year":"2001","journal-title":"Semin Oncol"},{"issue":"14","key":"10.1053\/j.tcam.2009.02.003_bib15","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJM199610033351403","article-title":"Esophagitis associated with the use of alendronate","volume":"335","author":"de Groen","year":"1996","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1053\/j.tcam.2009.02.003_bib16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.10-90001-3","article-title":"Preclinical perspectives on bisphosphonate renal safety","volume":"10","author":"Body","year":"2005","journal-title":"Oncologist"},{"issue":"1","key":"10.1053\/j.tcam.2009.02.003_bib17","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1523-1755.2003.00071.x","article-title":"Toxic acute tubular necrosis following treatment with zoledronate (Zometa)","volume":"64","author":"Markowitz","year":"2003","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.tcam.2009.02.003_bib18","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1681\/ASN.V1261164","article-title":"Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate","volume":"12","author":"Markowitz","year":"2001","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.tcam.2009.02.003_bib19","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/annonc\/mdj105","article-title":"Management of the adverse effects associated with intravenous bisphosphonates","volume":"17","author":"Tanvetyanon","year":"2006","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1053\/j.tcam.2009.02.003_bib20","first-page":"1241","article-title":"Assessment of bone mineral","volume":"25","author":"Wahner","year":"1984","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1053\/j.tcam.2009.02.003_bib21","first-page":"1134","article-title":"Assessment of bone mineral","volume":"25","author":"Wahner","year":"1984","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1053\/j.tcam.2009.02.003_bib22","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.2214\/ajr.155.5.2120933","article-title":"Detection of malignant bone tumors: MR imaging vs scintigraphy","volume":"155","author":"Frank","year":"1990","journal-title":"AJR Am J Roentgenol"},{"issue":"8","key":"10.1053\/j.tcam.2009.02.003_bib23","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3109\/07357909909032841","article-title":"Monitoring therapeutic response in skeletal metastases using dual-energy x-ray absorptiometry: a prospective feasibility study in breast cancer patients","volume":"17","author":"Shapiro","year":"1999","journal-title":"Cancer Invest"},{"issue":"4","key":"10.1053\/j.tcam.2009.02.003_bib24","first-page":"777","article-title":"Evaluation by dual energy X-ray absorptiometry of changed bone density in metastatic bone sites as a consequence of systemic treatment","volume":"7","author":"Berruti","year":"2000","journal-title":"Oncol Rep"},{"issue":"5","key":"10.1053\/j.tcam.2009.02.003_bib25","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1023\/A:1010991213842","article-title":"Dual x-ray absorptiometry detects disease- and treatment-related alterations of bone density in prostate cancer patients","volume":"18","author":"Smith","year":"2000","journal-title":"Clin Exp Metastasis"},{"issue":"1","key":"10.1053\/j.tcam.2009.02.003_bib26","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s005200050218","article-title":"Pamidronate treatment in patients with malignant osteolytic bone disease and pain: a prospective randomized double-blind trial","volume":"7","author":"Koeberle","year":"1999","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1053\/j.tcam.2009.02.003_bib27","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1939-1676.2005.tb02661.x","article-title":"Evaluation of intravenous pamidronate administration in 33 cancer-bearing dogs with primary or secondary bone involvement","volume":"19","author":"Fan","year":"2005","journal-title":"J Vet Intern Med"},{"issue":"2","key":"10.1053\/j.tcam.2009.02.003_bib28","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1939-1676.2008.0046.x","article-title":"The bone biologic effects of zoledronate in healthy dogs and dogs with malignant osteolysis","volume":"22","author":"Fan","year":"2008","journal-title":"J Vet Intern Med"},{"issue":"3","key":"10.1053\/j.tcam.2009.02.003_bib29","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1939-1676.2007.tb02986.x","article-title":"Single-agent pamidronate for palliative therapy of canine appendicular osteosarcoma bone pain","volume":"21","author":"Fan","year":"2007","journal-title":"J Vet Intern Med"},{"issue":"10","key":"10.1053\/j.tcam.2009.02.003_bib30","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S1470-2045(04)01596-7","article-title":"Assessment of therapeutic response in patients with metastatic bone disease","volume":"5","author":"Clamp","year":"2004","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1053\/j.tcam.2009.02.003_bib31","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/S0022-5347(05)65250-0","article-title":"Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer","volume":"167","author":"Koizumi","year":"2002","journal-title":"J Urol"},{"issue":"Suppl 12","key":"10.1053\/j.tcam.2009.02.003_bib32","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1002\/1097-0142(20000615)88:12+<2919::AID-CNCR7>3.0.CO;2-Z","article-title":"Biochemical markers and skeletal metastases","volume":"88","author":"Demers","year":"2000","journal-title":"Cancer"},{"issue":"13","key":"10.1053\/j.tcam.2009.02.003_bib33","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/S0959-8049(98)00277-9","article-title":"Markers of bone resorption in patients treated with pamidronate","volume":"34","author":"Lipton","year":"1998","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1053\/j.tcam.2009.02.003_bib34","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1200\/JCO.20.3.850","article-title":"Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status","volume":"20","author":"Costa","year":"2002","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.tcam.2009.02.003_bib35","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/jbmr.5650071119","article-title":"A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine","volume":"7","author":"Hanson","year":"1992","journal-title":"J Bone Miner Res"},{"issue":"12","key":"10.1053\/j.tcam.2009.02.003_bib36","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1373\/clinchem.2004.037424","article-title":"Assessment of urinary bone markers for monitoring treatment of osteoporosis","volume":"50","author":"Worsfold","year":"2004","journal-title":"Clin Chem"},{"issue":"4","key":"10.1053\/j.tcam.2009.02.003_bib37","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/j.1939-1676.2008.0134.x","article-title":"A comparison of five different bone resorption markers in osteosarcoma-bearing dogs, normal dogs, and dogs with orthopedic diseases","volume":"22","author":"Lucas","year":"2008","journal-title":"J Vet Intern Med"},{"issue":"1","key":"10.1053\/j.tcam.2009.02.003_bib38","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1939-1676.2007.0010.x","article-title":"In vivo and in vitro efficacy of zoledronate for treating oral squamous cell carcinoma in cats","volume":"22","author":"Wypij","year":"2008","journal-title":"J Vet Intern Med"},{"issue":"1","key":"10.1053\/j.tcam.2009.02.003_bib39","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1939-1676.2008.0221.x","article-title":"Double-blind placebo-controlled trial of adjuvant pamidronate with palliative radiotherapy and intravenous Doxorubicin for canine appendicular osteosarcoma bone pain","volume":"23","author":"Fan","year":"2009","journal-title":"J Vet Intern Med"},{"issue":"1","key":"10.1053\/j.tcam.2009.02.003_bib40","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000087286","article-title":"Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients","volume":"69","author":"Ferretti","year":"2005","journal-title":"Oncology"},{"issue":"8","key":"10.1053\/j.tcam.2009.02.003_bib41","first-page":"2893","article-title":"Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients","volume":"9","author":"Santini","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1053\/j.tcam.2009.02.003_bib42","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1089\/jir.2005.25.144","article-title":"Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients","volume":"25","author":"Vincenzi","year":"2005","journal-title":"J Interferon Cytokine Res"},{"issue":"6","key":"10.1053\/j.tcam.2009.02.003_bib43","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1892\/0891-6640(2005)19[924:BMEOSZ]2.0.CO;2","article-title":"Bone metabolic effects of single-dose zoledronate in healthy dogs","volume":"19","author":"de Lorimier","year":"2005","journal-title":"J Vet Intern Med"},{"issue":"1","key":"10.1053\/j.tcam.2009.02.003_bib44","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1939-1676.2005.tb02654.x","article-title":"Uses and effectiveness of pamidronate disodium for treatment of dogs and cats with hypercalcemia","volume":"19","author":"Hostutler","year":"2005","journal-title":"J Vet Intern Med"},{"issue":"1","key":"10.1053\/j.tcam.2009.02.003_bib45","doi-asserted-by":"crossref","first-page":"75","DOI":"10.5326\/0400075","article-title":"Electrolyte disturbances and cardiac arrhythmias in a dog following pamidronate, calcitonin, and furosemide administration for hypercalcemia of malignancy","volume":"40","author":"Kadar","year":"2004","journal-title":"J Am Anim Hosp Assoc"}],"container-title":["Topics in Companion Animal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1938973609000142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1938973609000142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T23:41:18Z","timestamp":1739317278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1938973609000142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S1938973609000142"],"URL":"https:\/\/doi.org\/10.1053\/j.tcam.2009.02.003","relation":{},"ISSN":["1938-9736"],"issn-type":[{"type":"print","value":"1938-9736"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}